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Bronchiectasis in children after renal or liver
transplantation: A report of five cases
Survival of transplanted organs and prognosis in
general has improved considerably in children
who receive an organ transplant (1). The
improved long-term survival is associated with
more extensive and more potent immunosup-
pressive treatment. Therefore, the side effects of
this treatment need more attention. The most
relevant side effect of immunosuppressive agents
is the increased susceptibility for (opportunistic)
infections, the lung being one of the vulnerable
sites.
Although not uncommon in developing coun-
tries, bronchiectasis is a rare disorder in children
in the western world; no recent data are available
on the incidence (2). Common causes of bron-
chiectasis are infections, and in developed coun-
tries, cystic fibrosis, immunodeficiencies and
ciliary dyskinesia (3). Obstructive lung disease
and bronchiectasis have been reported after bone
marrow transplantation, related to GVHD (4, 5).
In pediatric heart transplantation, recurrent
sinopulmonary infections and even bronchiecta-
sis were described in children who had their
transplant before the age of 4 yr. It was specu-
lated that impaired maturation of antipolysac-
charide responses caused by immunosuppression
may be responsible for recurrent and damaging
infections (6). Bronchiectasis as a radiographical
feature of bronchiolitis obliterans may be seen
after lung transplantation as part of chronic lung
allograft rejection (7). However, no reports on
bronchiectasis as a complication after liver or
kidney transplantation are found in the litera-
ture. We describe four pediatric patients with a
kidney transplant and one with a liver transplant,
who developed chronic and progressive pulmon-
ary symptoms, caused by bronchiectasis.
Patients
Characteristics of all five patients are summarized in
Table 1.
Patient 1, a boy from a family with high socioeconomic
status, received a cadaveric renal transplant at the age of
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Abstract: More effective immunosuppressive treatment in children fol-
lowing organ transplantation has significantly improved the survival of
the grafts. Therefore, quality of life, long-term prognosis and adverse
drug reactions have become more important. One of the main compli-
cations of immunosuppressive drugs is infections of the respiratory
tract, but irreversible damage to the airways has not been described
after renal or liver transplantation. Five children following transplan-
tation of kidney or liver were referred to the Paediatric Pulmonology
department because of chronic respiratory complaints. Pulmonary
function tests and HRCT scan were performed as routine patient care.
Four children with a renal transplant and one with a liver transplant
showed chronic bronchitis and moderate to severe airways obstruction.
HRCT showed bronchiectasis in all of them. We speculate that the
immunosuppressive treatment (in) directly contributes to irreversible
airway damage. We recommend including follow-up of lung function in
the post-transplantation protocol and considering bronchiectasis in case
of respiratory symptoms, to try preventing further damage to the lung.
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12.5 yr because of congenital renal dysplasia with vesico-
ureteral reflux. Chest X-ray at transplantation was normal.
Immunosuppressive prophylaxis consisted of corticoster-
oids, CsA and MMF; no induction treatment was used.
Three months after transplantation, the CsA levels were
between 75 and 125 mg/L, the MMF levels between 1.3 and
7 mg/L. Prednisone dose was 7.5 mg, once daily (0.16 mg/kg).
Acute rejection episodes did not occur. Three months after
transplantation, he had chickenpox, for which he was
treated with intravenous acyclovir. One year after trans-
plantation, he was treated for a Bordetella pertussis infection
(confirmed serologically), after which he recovered com-
pletely. Eighteen months later, he was referred to the pedi-
atric pulmonologist because of persistent productive
coughing. He did not have any prior primary pulmonary
complaints. PFT revealed severe airway obstruction
(Table 1). Sputum cultures grew Pseudomonas aeruginosa
and HRCT scan showed bronchiectasis in both lower lobes
(Fig. 1). He was treated with ciprofloxacin, nebulized
tobramycin and DNase, and PEP by mask. Despite this
treatment, he had a severe exacerbation of symptoms at
the age of 16.5 years, when BALF showed Streptococcus
pneumoniae and rhinovirus. No other pathogens were
found. He was treated with intravenous cefuroxim and
recovered only slowly and incompletely. Cystic fibrosis and
primary ciliary dyskinesia were ruled out by appropriate
tests. It was hypothesized that the bronchiectasis could be
explained by the proven B. pertussis infection.
However, within 18 months of this referral, four other
patients on immunosuppressive treatment following kidney
(3) or liver (1) transplantation were referred because of
similar symptoms. They all presented with chronic pro-
ductive cough without fever, dyspnea and with diminished
exercise tolerance. The initial immunosuppressive therapy
was the same for all four kidney transplant patients and
consisted of corticosteroids, CsA and MMF. No induction
therapy was administered. From 6 months post-transplant,
the dosage of prednisolone was 5 mg/m2/day, and MMF
600 mg/m2 b.i.d.; CsA dosage was titrated to a serum con-
centration of 100 mg/L. In two cases (patients 3 and 4),
cyclosporin was discontinued at 6 months post-transplan-
tation in the framework of a study protocol. In patient 5,
CsA was discontinued and replaced by MMF because of
minimal impairment of renal function. Chest X-rays on the
day of transplantation were normal in all patients. Kidney
transplant patients 1, 2 and 4 received antibiotics continu-
ously for urinary tract infection prophylaxis. The diagnostic
workup, similar to patient 1, did not reveal any indication
for the common causes of bronchiectasis. Patients 2 and 3
are from families with low income; the families of patients 4
and 5 are prosperous.
Patient 2 had a renal transplant at the age of 2 yr because
of renal failure after perinatal asphyxia. Chronic pyelone-
Table 1. Characteristics of five children who had kidney or liver transplantation and subsequently developed bronchiectasis
Male, 17 yr Male, 12 yr Male, 11 yr Male, 7 yr Female, 11 yr
Age at TX (yr) 12 10 (second TX) 7 3 0.8
Age at respiratory
symptoms (yr)
15 11 8 5 7
Primary diagnosis Renal dysplasia Asphyxia Mesangioproliferative
glomerulonephritis
Congenital nephrotic
syndrome
Biliary atresia
Transplanted organ Kidney Kidney Kidney Kidney Liver
Creatinine (lmol/L) 250 85 65 60
Immunosuppression P, CsA, MMF P, CsA, MMF P, CsA*, MMF P, CsA*, MMF P, CsA, MMF
Sputum cultures Pseudomonas aeruginosa Haemophilus influenzae Haemophilus influenzae Haemophilus influenzae Haemophilus
parainfluenzae
Streptococcus pneumoniae Haemophilus parainfluenzae
Stenotrophomonas maltophilia
Flavobacterium species
Pseudomonas aeruginosa
FVC (% pred) ** 69/91 67/100 61/92 66/101 94/88
FEV1 (% pred)** 59/80 56/103 51/71 72/101 88/81
FEV1/FVC (%)** 71/73 69/86 70/64 93/84 80/79
MEF 25 (% pred)** 11/28 17/68 13/23 28/43 45/36
Location bronchiectasis Both lower lobes,
right upper lobe
Left lower lobe Generalized Right middle lobe,
lingula
Both lower lobes,
lingula
TX, transplant; P, prednisone; CsA, cyclosporin A; MMF, mycophenolate mofetil; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; MEF 25, maximal
expiratory flow at 25% of vital capacity.
*prescribed during the first half year after transplantation, **at referral to the Department of Pediatric Respiratory Medicine/maximal value after treatment.
Fig. 1. Slide of HRCT scan, showing bronchiectasis in
patient 1.
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phritis led to failure of this graft at the age of 8 yr, after
which he was treated with peritoneal dialysis. A second
transplant with a kidney from his mother was performed at
the age of 9 yr. As a toddler, the boy had recurrent ear, nose
and throat infections, treated with adenotonsillectomy and
bilateral ventilation tubes. Chest X-ray before transplanta-
tion was unremarkable. One year after his second transplant
he presented with chronic productive cough and recurrent
pansinusitis. Sputum culture revealed Haemophilus influen-
zae and the chest X-ray showed increased markings. On
HRCT, bronchiectasis in the left lower lobe was detected.
The boy was treated with amoxicillin, DNase and PEP mask
and only recovered slowly, partly because of low adherence
to treatment.
A 11-yr-old boy was the third referral to our pediatric
pulmonology department. He received a kidney transplant
from his father at the age of 7 yr and presented with res-
piratory symptoms 1 yr later. His primary diagnosis was
mesangioproliferative glomerulonephritis. At first presen-
tation, severe airway obstruction was present. Sputum cul-
tures revealed H. influenzae. He was treated with antibiotics
based on sensitivity tests. However, his lung function did
not recover and HRCT scan showed bronchiectasis. DNase
was added and he was treated with a PEP mask. When he
presented with an exacerbation of his complaints, a broncho-
scopy was performed and BALF grew H. influenzae, and
no opportunistic microorganisms. At 3 yr after referral,
sputum was colonized with Pseudomonas aeruginosa, and
the patient was treated with ciprofloxacin and tobramycin
inhalations. Stenotrophomonas infection was treated with
cotrimoxazole. At the last follow-up visit, he had a pro-
ductive cough and crackles bilaterally on chest auscultation.
His pulmonary function tests improved significantly, but did
not recover fully.
The fourth patient was a 3-yr-old, who received a
cadaveric kidney transplant for congenital nephrotic syn-
drome. Two years later, he presented with chronic produc-
tive cough; sputum culture grew H. influenzae and he was
treated with amoxicillin/clavulanic acid. As symptoms
persisted, antibiotics were switched to clarithromycin and
nebulizations with DNase and PEP therapy were started.
Only after an intravenous course of cefuroxime, did his
pulmonary function normalize and symptoms disappeared.
No other pathogens besides H. influenzae were cultured.
Bronchoscopy and BAL were not performed.
A 11-yr-old girl was the fifth patient who developed
bronchiectasis after a solid organ transplantation. She
received a cadaveric donor liver because of biliary atresia
when she was 10 months old. Initial immunosuppression
consisted of prednisone, azathioprine and CsA. CsA was
discontinued after 1 yr, but restarted at the age of 6 yr
because of signs of rejection on a liver biopsy. Five years
after transplantation, azathioprine was replaced with MMF.
CsA was withdrawn after introduction of MMF. At the age
of 9 yr, she presented with chronic cough and diminished
exercise tolerance for 1.5 yr. Immunosuppression at that
time consisted of MMF 500 mg b.i.d. and prednisone 12 mg
on alternate days. MMF levels varied between 3.5 and
9.6 mg/L (4.0 mg/L at presentation). Immunoglobulins were
within normal limits. Her pulmonary history was previously
unremarkable, however, she had had recurrent ear, nose,
and throat infections. Except for one antibiotic course, the
patient did not receive any antibiotic treatment. In her
sputum, Haemophilus parainfluenzae was cultured. The girl
was treated with cotrimoxazole, DNase and PEP therapy.
However, pulmonary function tests have not improved.
Discussion
This is the first report of bronchiectasis in
children who underwent a kidney or liver trans-
plantation. Airway infection with bronchial
obstruction and retention of mucus are major
factors in the pathogenesis of bronchiectasis (3).
Well-known causes of bronchiectasis in children
in the western world are cystic fibrosis, mucocil-
iary clearance defects, recurrent aspiration and
immunodeficiencies, but in up to 50% of patients
with bronchiectasis, no cause is identified (8). In
our current pediatric renal transplant popula-
tion, we diagnosed bronchiectasis in four of 38
patients. Bronchiectasis has been reported after
pediatric bone marrow, heart, heart–lung and
lung transplantation (4–7). In bone marrow
transplantation, bronchiectasis is associated with
chronic GVHD (4). In adult bone marrow
recipients, it was shown that ciliary beat fre-
quency was severely reduced in those patients
who developed bronchiolitis obliterans and
chronic GVHD (9). Impaired maturation of anti-
polysaccharide responses caused by immunosup-
pression may be responsible for recurrent
infections leading to bronchiectasis, especially
in children transplanted before the age of 4 yr, as
was shown for pediatric heart transplant recip-
ients (6).
Several mechanisms may account for the
development of bronchiectasis in our patients.
First, all patients have secondary immunodefi-
ciency caused by immunosuppressive medication,
which may have facilitated pulmonary infections.
Besides, pulmonary infections may have been
masked by the prophylactic antibiotic treatment
these patients received to prevent urinary tract
infections. We cannot exclude that the patients
had opportunistic infections, but could not
identify such microorganisms despite broncho-
scopy with lavage in two patients. Patient 1 had
had a serologically proven B. pertussis infection,
a well-known but rare cause of bronchiectasis,
18 months before he presented with bronchiec-
tasis.
As we did not feel lung biopsy would provide
us with useful information or would change our
treatment, lung biopsies were not performed in
our patients.
An alternative hypothesis is that the immuno-
suppressive drugs were a causative factor. All
patients used one shared immunosuppressive
drug, MMF, a relatively new drug in our
immunosuppressive regime, for a prolonged
period of time. Pulmonary side effects of MMF
have been described: coughing, bronchitis and
shortness of breath. Two case reports document
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acute respiratory failure with pulmonary fibrosis
and pneumonitis most likely caused by MMF,
but bronchiectasis is not known as an adverse
effect of MMF (10, 11). In vivo, MMF severely
depresses humoral immunity making patients
more susceptible to infection (12). Before the
introduction of MMF in our standard immuno-
suppression regime in 1997, we had not seen any
patient with bronchiectasis after transplantation.
We speculate that MMF may play a role in the
development of bronchiectasis in our patients by
facilitating or masking pulmonary infections
more than other immunosuppressive drugs or
by exerting a direct effect on the airway wall.
Obviously, the exact mechanism remains to be
elucidated and requires further research.
Therapeutic levels of CsA are not associated
with serious pulmonary toxicity.
In our patients, no data on pre-transplant PFT
were available nor did we have any pre-transplant
CT scans. Diminished lung volumes have been
described in chronic renal failure, but most trans-
planted patients showed normal spirometry
(13, 14). We cannot exclude pre-transplant abnor-
malities in PFT in our patients, but there were no
respiratory symptoms prior to transplantation.
As prognosis and survival of children after
organ transplantation increased dramatically in
the past decade, complications of the post-
transplant therapy have become more and more
important and may co-determine long-term
prognosis (1). Once structural abnormalities of
the bronchi are present, even control of infection
and inflammation may not be sufficient to arrest
the progression to disable irreversible airway
obstruction.
In the presence of respiratory symptoms,
bronchiectasis should be considered and, as
spirometry is not sensitive enough in detecting
early structural lung damage, HRCT should be
performed (2, 15). However, we recommend
including follow-up of lung function in the
post-transplantation protocol as well, as periph-
eral airway obstruction may be a sign of bron-
chiectasis. By aggressively treating children with
bronchiectasis who are receiving immunosup-
pressive drugs, further damage to the lung may
be prevented and quality of life and long-term
prognosis improved.
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